ZA201808423B - Heteroaryl substituted pyridines and methods of use - Google Patents
Heteroaryl substituted pyridines and methods of useInfo
- Publication number
- ZA201808423B ZA201808423B ZA2018/08423A ZA201808423A ZA201808423B ZA 201808423 B ZA201808423 B ZA 201808423B ZA 2018/08423 A ZA2018/08423 A ZA 2018/08423A ZA 201808423 A ZA201808423 A ZA 201808423A ZA 201808423 B ZA201808423 B ZA 201808423B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- heteroaryl substituted
- substituted pyridines
- pyridines
- heteroaryl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345315P | 2016-06-03 | 2016-06-03 | |
| PCT/IB2017/053068 WO2017208115A1 (en) | 2016-06-03 | 2017-05-24 | Heteroaryl substituted pyridines and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201808423B true ZA201808423B (en) | 2019-08-28 |
Family
ID=59014678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/08423A ZA201808423B (en) | 2016-06-03 | 2018-12-13 | Heteroaryl substituted pyridines and methods of use |
Country Status (35)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100921397B1 (ko) * | 2009-02-09 | 2009-10-14 | (주)오엠티 | 인쇄회로기판의 세척장비 및 이를 이용한 세척방법 |
| MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| JP7121794B2 (ja) | 2017-08-02 | 2022-08-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリジン化合物を調製するためのプロセス |
| US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| EP3720849A2 (en) | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| JP7214743B2 (ja) | 2018-02-15 | 2023-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 |
| US10710994B2 (en) * | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| IT201900000687A1 (it) | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento della fibrosi cistica |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| MX2022005809A (es) * | 2019-11-12 | 2022-06-08 | Genzyme Corp | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr). |
| EP4058434A1 (en) | 2019-11-12 | 2022-09-21 | Genzyme Corporation | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| WO2022040447A2 (en) | 2020-08-20 | 2022-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating respiratory diseases characterized by mucus hypersecretion |
| KR20230118123A (ko) | 2020-12-10 | 2023-08-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 치료 방법 |
| US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| EP4274828A1 (en) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| AU2022331725A1 (en) | 2021-08-19 | 2024-03-07 | Syngenta Crop Protection Ag | Method for controlling diamide resistant pests & compounds therefor |
| WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
| CA3267788A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND/OR CFTR POTENTIALIZERS |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1740532A4 (en) * | 2004-03-30 | 2009-06-10 | Univ California | CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF |
| CA2569402A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| EP2142498A2 (en) * | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Cftr inhibitor compounds and uses thereof |
| JP5686596B2 (ja) | 2007-05-25 | 2015-03-18 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 |
| MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| JP5637859B2 (ja) | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
| CN102224141B (zh) | 2008-10-23 | 2014-10-08 | 沃泰克斯药物股份有限公司 | N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式 |
| EP2349263B1 (en) * | 2008-10-23 | 2014-04-23 | Vertex Pharmaceuticals Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| KR101886459B1 (ko) | 2010-10-08 | 2018-08-07 | 니발리스 테라퓨틱스, 인코포레이티드 | S-나이트로소글루타티온 리덕타제 억제제로서의 신규한 치환된 퀴놀린 화합물 |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| CN103946221B (zh) * | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US9056867B2 (en) * | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| AU2012312520A1 (en) | 2011-09-20 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by PLUNC proteins |
| WO2014180562A1 (en) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
| PT3030568T (pt) | 2013-08-08 | 2018-12-24 | Galapagos Nv | Tieno[2,3-c]piranos como moduladores de cftr |
| US9745292B2 (en) | 2014-03-13 | 2017-08-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| WO2015138909A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| MX2017005663A (es) | 2014-10-31 | 2018-03-01 | Abbvie Sarl | Tetrahidropiranos sustituidos y metodo de uso. |
| DK3212189T3 (da) | 2014-10-31 | 2020-10-26 | Abbvie Overseas Sarl | Substituerede chromaner og fremgangsmåde til anvendelse deraf |
| EP3277647A1 (en) * | 2015-03-31 | 2018-02-07 | Vertex Pharmaceuticals (Europe) Limited | Deuterated vx-661 |
| US10047051B2 (en) * | 2015-06-02 | 2018-08-14 | Abbvie S.Á.R.L. | Substituted pyridines and method of use |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| TW201735769A (zh) | 2015-10-09 | 2017-10-16 | 盧森堡商艾伯維公司 | 經取代之吡唑并［３，４－ｂ］吡啶－６－羧酸及使用方法 |
| BR112018007161B1 (pt) | 2015-10-09 | 2024-01-16 | Galapagos Nv | COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA |
| AU2017256172A1 (en) | 2016-04-26 | 2018-09-06 | AbbVie S.à.r.l. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
-
2017
- 2017-05-23 US US15/602,892 patent/US10138227B2/en active Active
- 2017-05-24 CN CN202210433324.9A patent/CN114671864B/zh active Active
- 2017-05-24 DK DK17728272.0T patent/DK3464282T3/da active
- 2017-05-24 RS RS20200829A patent/RS60574B1/sr unknown
- 2017-05-24 JP JP2018552704A patent/JP6968094B2/ja active Active
- 2017-05-24 CA CA3022216A patent/CA3022216A1/en active Pending
- 2017-05-24 EP EP17728272.0A patent/EP3464282B1/en active Active
- 2017-05-24 KR KR1020187031861A patent/KR102469995B1/ko active Active
- 2017-05-24 MX MX2018014758A patent/MX385054B/es unknown
- 2017-05-24 IL IL288243A patent/IL288243B2/en unknown
- 2017-05-24 SG SG11201808842VA patent/SG11201808842VA/en unknown
- 2017-05-24 PE PE2018003091A patent/PE20190511A1/es unknown
- 2017-05-24 ES ES17728272T patent/ES2806873T3/es active Active
- 2017-05-24 IL IL303196A patent/IL303196B2/en unknown
- 2017-05-24 HU HUE17728272A patent/HUE050248T2/hu unknown
- 2017-05-24 CN CN201780033214.0A patent/CN109311864B/zh active Active
- 2017-05-24 AU AU2017273215A patent/AU2017273215B2/en active Active
- 2017-05-24 PL PL17728272T patent/PL3464282T3/pl unknown
- 2017-05-24 CR CR20180547A patent/CR20180547A/es unknown
- 2017-05-24 WO PCT/IB2017/053068 patent/WO2017208115A1/en not_active Ceased
- 2017-05-24 MY MYPI2018703798A patent/MY199604A/en unknown
- 2017-05-24 RU RU2018138707A patent/RU2756743C2/ru active
- 2017-05-24 LT LTEP17728272.0T patent/LT3464282T/lt unknown
- 2017-05-24 SM SM20200394T patent/SMT202000394T1/it unknown
- 2017-05-24 SI SI201730320T patent/SI3464282T1/sl unknown
- 2017-05-24 HR HRP20201068TT patent/HRP20201068T1/hr unknown
- 2017-05-24 PT PT177282720T patent/PT3464282T/pt unknown
- 2017-05-24 RU RU2021127810A patent/RU2021127810A/ru unknown
- 2017-05-24 KR KR1020227040379A patent/KR102719916B1/ko active Active
- 2017-06-02 UY UY0001040612A patent/UY40612A/es not_active Application Discontinuation
- 2017-06-02 AR ARP170101516A patent/AR108672A1/es active IP Right Grant
- 2017-06-02 UY UY0001037272A patent/UY37272A/es active IP Right Grant
- 2017-06-03 TW TW112108367A patent/TWI849782B/zh active
- 2017-06-03 TW TW113122971A patent/TW202515560A/zh unknown
- 2017-06-03 TW TW110149319A patent/TWI797926B/zh active
- 2017-06-03 TW TW106118418A patent/TWI752961B/zh active
-
2018
- 2018-10-16 IL IL262415A patent/IL262415B/en unknown
- 2018-10-19 US US16/165,662 patent/US10604515B2/en active Active
- 2018-11-13 CO CONC2018/0012171A patent/CO2018012171A2/es unknown
- 2018-11-22 CL CL2018003323A patent/CL2018003323A1/es unknown
- 2018-11-26 DO DO2018000257A patent/DOP2018000257A/es unknown
- 2018-11-29 MX MX2021009322A patent/MX2021009322A/es unknown
- 2018-11-29 PH PH12018502534A patent/PH12018502534B1/en unknown
- 2018-12-13 ZA ZA2018/08423A patent/ZA201808423B/en unknown
- 2018-12-26 EC ECSENADI201894790A patent/ECSP18094790A/es unknown
-
2020
- 2020-07-14 CY CY20201100646T patent/CY1124031T1/el unknown
-
2021
- 2021-10-25 JP JP2021173679A patent/JP7392211B2/ja active Active
- 2021-12-07 AU AU2021282409A patent/AU2021282409B2/en not_active Expired - Fee Related
-
2022
- 2022-02-18 AR ARP220100344A patent/AR124916A2/es unknown
-
2023
- 2023-03-27 JP JP2023049450A patent/JP7622122B2/ja active Active
-
2024
- 2024-04-16 AU AU2024202468A patent/AU2024202468A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288243A (en) | Heteroaryl-substituted pyridines and methods of use | |
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL256032A (en) | Substituted pyridines and method of use | |
| HUE055417T2 (hu) | Inzulin-Fc fúziók és alkalmazási eljárások | |
| HUE068842T2 (hu) | Vegyületek és alkalmazási eljárásaik | |
| EP3122728A4 (en) | Substituted heteroaryl compounds and methods of use | |
| IL248529B (en) | Palladianolide pyridine compounds and methods of use | |
| EP3206691A4 (en) | Substituted heteroaryl compounds and methods of use | |
| GB2546006B (en) | Downhole apparatus and methods of use | |
| SG11201605917SA (en) | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use | |
| GB2549052B (en) | Wellbore isolation devices and methods of use | |
| SMT202500476T1 (it) | Winguide e metodo di utilizzo dello stesso | |
| SG10201913045PA (en) | A solid state form of pladienolide pyridine compounds and methods of use | |
| EP3448375C0 (en) | BENZOYLGLYCINE DERIVATIVES AND METHODS OF PRODUCING AND USING SUCH DERIVATIVES | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| GB2549053B (en) | Wellbore isolation devices and methods of use | |
| GB2549054B (en) | Wellbore isolation devices and methods of use | |
| GB201600844D0 (en) | Garment and method of use thereof | |
| GB201522746D0 (en) | Downhole apparatus and methods of use | |
| GB201501469D0 (en) | Garment and method of use thereof | |
| GB201404133D0 (en) | Garment and method of use thereof |